Drilldown: Medicines

Choose a table:

Medicines (732)

Medicines > duration

: 4-6 hours

or Daily dosing

or N/A

Use the filters below to narrow your results.

None (7) · Acetaminophen (paracetamol, APAP) (1) · Albuterol (1) · Bumetanide (1) · Butalbital / Acetaminophen / Caffeine (1) · Butalbital / Aspirin / Caffeine (1) · Codeine / Acetaminophen (1) · Diphenhydramine (hydrochloride; citrate) (1) · Fluorouracil (5-FU) (1) · Hydroxyzine (hydrochloride; pamoate salt) (1) · Ibuprofen (1) · Ipratropium bromide (1) · Ketorolac (tromethamine) (1) · Methocarbamol (1) · Metoclopramide (1) · Omega-3-acid ethyl esters (1) · Oxycodone / Acetaminophen (1) · Oxycodone / Aspirin (1) · Polyethylene glycol 3350 with electrolytes (1) · Promethazine (hydrochloride) (1) · Psilocybin (1) · Riboflavin (vitamin B2) (1) · Tramadol / Acetaminophen (1) · Tretinoin (all-trans retinoic acid, ATRA) (1)

Advil, Motrin, IBU, Caldolor (IV), NeoProfen (neonatal IV) (1) · Atrovent (inhaler, intranasal); also generic (1) · Benadryl (oral, injectable, topical), Banophen, Sominex (sleep aid), ZzzQuil, Aler-Dryl (1) · Bumex (1) · Caplyta (1) · COMP360 (Compass Pathways, investigational synthesized clinical formulation) (1) · Efudex (topical), Carac (topical), Fluoroplex (topical); generic IV (1) · Fioricet, Esgic; with codeine as Fioricet with Codeine (Schedule III) (1) · Fiorinal; with codeine as Fiorinal with Codeine (Schedule III) (1) · GoLYTELY, NuLYTELY, TriLyte, MoviPrep, Plenvu, Gavilyte (1) · Lovaza, Omtryg (1) · Many generics/OTC (1) · Nuplazid (1) · Percocet, Endocet, Roxicet, Tylox, Primlev (1) · Percodan (1) · Phenergan, Promethegan (suppositories) (1) · Qelbree (1) · Reglan, Gimoti (intranasal), Metozolv ODT (1) · REL-1017 / esmethadone (investigational; not yet FDA-approved as of mid-2024) (1) · Retin-A, Renova, Atralin, Avita, Tretin-X, Refissa, Altreno; Vesanoid (oral, APL) (1) · Rexulti (1) · Robaxin (oral, injectable) (1) · Toradol (IV/IM, US brand discontinued), Sprix (nasal spray), Acular and Acuvail (ophthalmic) (1) · Trintellix (US), Brintellix (formerly) (1) · Tylenol with Codeine #3 (30 mg codeine), Tylenol #4 (60 mg codeine), Capital with Codeine, Phenaphen with Codeine (1) · Tylenol, Panadol (international), Ofirmev (IV); huge OTC presence (1) · Ultracet, Tramacet (1) · Ventolin, ProAir, Proventil, AccuNeb (1) · Viibryd (1) · Vistaril (pamoate), Atarax (HCl, discontinued in US as brand) (1)

Other values:

0.5-1 mg PO/IV once or twice daily; titrate to clinical response. Approximate equipotency: bumetanide 1 mg ≈ furosemide 40 mg ≈ torsemide 20 mg (1) · 1 tablet (4.8355 mg oxycodone / 325 mg aspirin) PO every 6 hours as needed (1) · 1-2 capsules (50 mg butalbital / 325 mg acetaminophen / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d (1) · 1-2 capsules (50 mg butalbital / 325 mg aspirin / 40 mg caffeine each) PO every 4 hours as needed; maximum 6 capsules/d (1) · 1-2 tablets (15-60 mg codeine, 300-600 mg acetaminophen) PO every 4-6 hours as needed (1) · 10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food) (1) · 10 mg PO once daily; may increase to 20 mg as tolerated, or decrease to 5 mg if needed (1) · 10 mg PO/IV/IM QID, '''not to exceed 12 weeks''' (tardive dyskinesia risk); intranasal Gimoti 15 mg BID (1) · 2 tablets (75 mg tramadol / 650 mg acetaminophen) PO every 4-6 hours as needed; maximum 8 tablets/day for ≤5 days (1) · 200-400 mg PO every 4-6 hours as needed. OTC max 1200 mg/day without provider direction; prescription max 3200 mg/day divided (1) · 325-1000 mg PO every 4-6 hours as needed; maximum 4 g/d in healthy adults, 3 g/d in regular users or hepatic risk; pediatric 10-15 mg/kg every 4-6 hours (1) · 34 mg PO once daily (1) · 4 g PO daily (as 4 x 1 g capsules once daily, or 2 capsules BID) (1) · 4 L oral solution (GoLYTELY-class) split-dose: 2 L evening before, 2 L morning of procedure; low-volume products (MoviPrep, Plenvu) use 1-2 L with required clear-fluid intake (1) · 42 mg PO once daily with food (no titration) (1) · 5 mg / 325 mg PO every 4-6 hours as needed; total acetaminophen <3 g/d (1) · Allergy: 25 mg PO BID-QID. Nausea/vomiting: 12.5-25 mg PO/IM/IV/PR every 4-6 hours. Motion sickness: 25 mg PO 30-60 minutes before travel. '''Pediatric <2 years: contraindicated''' (1) · Allergy: 25-50 mg PO every 4-6 hours. Insomnia: 25-50 mg PO at bedtime. IV (acute dystonia, severe allergic reaction): 25-50 mg slow IV push (1) · Anxiety: 25-50 mg PO QID. Pruritus: 25 mg PO TID-QID. Insomnia: 25-50 mg PO at bedtime. Pediatric: 50-100 mg/day divided (1) · IM: 60 mg single dose or 30 mg every 6 hours. IV: 30 mg every 6 hours. Oral (continuation only): 10-20 mg every 4-6 hours. Sprix nasal: 31.5 mg every 6-8 hours. '''Maximum 5 days total combined use''' (1) · MDI 90 mcg/puff, 2 puffs q4-6h prn; nebulized 2.5 mg in 3 mL saline q4-6h (1) · Migraine prophylaxis: 400 mg PO daily; deficiency replacement 5-30 mg/d (1) · Modern clinical-trial standard: 25 mg synthesized psilocybin, single oral dose with psychological support (1) · Nebulized 500 mcg q6-8h (or with albuterol as DuoNeb); MDI 17 mcg/puff, 2 puffs QID; nasal 0.03% or 0.06% spray BID-TID (1) · Oral: 1500 mg PO QID for 2-3 days (load), then 750-1500 mg QID maintenance. IV/IM: 1000 mg every 8 hours for acute spasm (1) · Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. (1) · Schizophrenia: 1 mg PO daily × 4 days, then 2 mg daily × 3 days, then 4 mg daily. MDD adjunct: 0.5-1 mg daily, increase to 2 mg max. AD agitation: 0.5 mg daily, titrate to 2-3 mg daily. (1) · Topical: 0.5-5% cream/solution to lesions BID × 2-4 weeks; systemic IV: regimen-specific in cancer chemotherapy (1) · Topical: pea-sized amount to dry face at bedtime, building from 2-3×/week to nightly as tolerated; oral APL: 45 mg/m²/d in divided doses (1) · Trials use 25 mg or 50 mg PO daily (1)

0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg tablets (1) · 0.5% (Carac), 1% (Fluoroplex), 5% (Efudex) topical creams/solutions; 50 mg/mL IV (1) · 0.5, 1, 2 mg tablets; 0.25 mg/mL IV (1) · 1 g soft gelatin capsules containing ~465 mg EPA + ~375 mg DHA as ethyl esters (1) · 10 mg, 20 mg, 40 mg tablets (1) · 10 mg, 34 mg capsules/tablets (1) · 100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food) (1) · 25, 50, 100, 250, 400 mg tablets; OTC (1) · 325, 500, 650 mg tablets; 80, 160 mg chewables; 160 mg/5 mL pediatric liquid; 325 mg suppository; 1000 mg/100 mL IV (Ofirmev); fixed-dose combinations with opioids, decongestants, antihistamines (1) · 4.8355 mg oxycodone / 325 mg aspirin tablets (1) · 42 mg capsules (1) · 5 mg, 10 mg, 20 mg tablets (1) · 5, 10 mg tablets; 5 mg/5 mL solution; 5 mg/mL IV; 15 mg/spray intranasal (1) · 50/325/40 mg capsules (1) · 50/325/40 mg capsules and tablets; oral solution (1) · Atrovent HFA 17 mcg/actuation MDI; 500 mcg/2.5 mL nebulizer solution; 0.03% and 0.06% intranasal sprays; with albuterol as DuoNeb / Combivent Respimat (1) · Codeine/acetaminophen 15/300 (#2 historical), 30/300 (#3), 60/300 (#4) mg tablets; 12/120 mg/5 mL elixir (1) · Investigational oral capsule (1) · MDI 90 mcg/puff; nebulizer solution 0.083% (2.5 mg/3 mL), 0.5%, 0.021%, 0.042%; syrup 2 mg/5 mL; 2 mg, 4 mg tablets; 4 mg, 8 mg ER (1) · Oxycodone/acetaminophen 2.5/325, 5/325, 7.5/325, 10/325 mg tablets; 5/325 mg/5 mL solution (1) · Powder for oral solution in 4 L jugs (PEG 3350 ~236 g + NaCl, NaHCO3, KCl, Na2SO4) and low-volume packets (1) · Synthesized psilocybin capsules (COMP360 and other investigational formulations); dried whole [[Psilocybe|Psilocybe]] mushrooms (variable potency, no legal supply chain in most jurisdictions); psilocybin truffles (Psilocybe sclerotia, legal in the Netherlands) (1) · Tablets 10 mg; injection 15 mg/mL and 30 mg/mL; nasal spray 15.75 mg/spray (Sprix); ophthalmic solution 0.4%, 0.45%, 0.5% (1) · Tablets 10, 25, 50 mg (HCl); capsules 25, 50, 100 mg (pamoate); oral suspension 25 mg/5 mL; injection 25, 50 mg/mL (IM only, never IV) (1) · Tablets 12.5, 25, 50 mg; oral syrup 6.25 mg/5 mL; suppositories 12.5, 25, 50 mg; injection 25 mg/mL and 50 mg/mL (1) · Tablets 200, 400, 600, 800 mg; capsules 200 mg; oral suspension 100 mg/5 mL; chewable tablets 100 mg; injection 100 mg/mL (Caldolor) (1) · Tablets 25, 50 mg; capsules; liquid; chewable; topical cream/gel; injection 50 mg/mL (1) · Tablets 500, 750 mg; injection 100 mg/mL (1) · Topical 0.01-0.1% creams, gels, micropsheres, lotions; oral 10 mg capsules (Vesanoid) (1) · Tramadol/acetaminophen 37.5/325 mg tablets (1)

100 mg/day (adult) (1) · 12 inhalations/d (rescue); higher for severe exacerbation under monitoring (1) · 12 puffs MDI/d typical; nebulized 2000 mcg/d (1) · 120 mg/day (IV/IM); 40 mg/day (oral); '''5-day maximum total combined therapy''' to mitigate the GI bleeding, AKI, and platelet dysfunction risks (1) · 20 mg/d (1) · 300 mg/day (oral) (1) · 3200 mg/day (Rx); 1200 mg/day (OTC, without provider direction) (1) · 34 mg/d (1) · 4 g/d (1) · 4 g/d in healthy adults; 3 g/d conservative limit; 2 g/d in cirrhosis or chronic alcohol use (1) · 4 L per procedure (standard-volume products) (1) · 4 mg/d (schizophrenia); 3 mg/d (AD agitation); 3 mg/d (MDD adjunct) (1) · 40 mg/d (2) · 400 mg/d (pediatric); 600 mg/d (adult) (1) · 400 mg/day theoretical; in practice rarely exceeds 200 mg/day (1) · 42 mg/d (1) · 6 capsules/d (300 mg butalbital, 1950 mg acetaminophen, 240 mg caffeine) (1) · 6 capsules/d (300 mg butalbital, 1950 mg aspirin, 240 mg caffeine) (1) · 8 g/day (oral, short-term load); 6 g/day (chronic) (1) · 8 tablets/d (300 mg tramadol / 2600 mg acetaminophen); 5-day duration limit per label (1) · Acetaminophen 4 g/d absolute (3 g/d conservative); oxycodone titrated to effect (1) · Acetaminophen 4 g/d absolute; codeine 240-360 mg/d typical practical limit (1) · Aspirin GI/bleeding-limited; oxycodone titrated to effect (1) · No strict ceiling for water-soluble vitamin; UL not set (1) · Not FDA-approved; clinical-trial protocols use up to 30 mg in adult investigational dosing (1) · Not yet approved (1) · Topical: nightly; oral APL: 45 mg/m²/d (1) · Topical: nightly; systemic: regimen-specific (1) · ~10 mg/d typical (1)

IM (5) · Inhaled (MDI (2) · intramuscular (2) · intranasal (3) · intravenous (1) · intravenous (Caldolor (1) · IV (6) · IV (rare) (1) · IV (with caution) (1) · nebulized) (2) · NeoProfen) (1) · ophthalmic (1) · Oral (26) · oral (APL only) (1) · Oral (continuation only) (1) · rectal (2) · Topical (3)

10-30 minutes (1) · 15-30 minutes (1) · 15-30 minutes (oral) (1) · 15-30 minutes (oral); 1-2 minutes (IV) (1) · 20 minutes (oral); 5 minutes (IV) (1) · 20-45 min subjective onset; psilocin formation from psilocybin requires intestinal and hepatic alkaline phosphatase (1) · 30 minutes (IM); 30-60 minutes (oral) (1) · 30-60 minutes (4) · 30-60 minutes (oral) (1) · 4-6 weeks for full antidepressant effect (claimed earlier onset for some patients due to 5HT1A partial agonism) (1) · ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks) (1) · Antipsychotic effect over weeks (1) · Benefit over weeks of dosing (1) · Bronchodilation 15-30 minutes (1) · First bowel movement within 1-2 hours (1) · Inhaled: 5-15 minutes; PO: 30 minutes (1) · IV/IM 1-3 minutes; PO 30-60 minutes (1) · Migraine effect after 1-3 months of daily use (1) · PO 30-60 minutes; IV minutes (1) · PO: 30-60 minutes; IV: minutes (1) · Rapid (within 1 week in trials) (1) · Topical: inflammation, erythema, crusting at 2 weeks; complete response weeks to months after course (1) · Topical: irritation within days; acne improvement 6-12 weeks; oral APL response within days (1) · Triglyceride lowering at 2-4 weeks; max at 8 weeks (1) · Typical antidepressant 4-6 week onset (1) · Weeks for psychosis/depression; AD agitation benefit emerges over weeks (1) · ~30 minutes (oral) (1)

Adequate oral bioavailability with extended-release formulation (1) · Butalbital well-absorbed; aspirin 50-75%; caffeine ~100%'"`UNIQ--ref-000015B8-QINU`"' (1) · Butalbital well-absorbed; caffeine ~100%; acetaminophen 85-98%'"`UNIQ--ref-000015A0-QINU`"' (1) · Codeine ~60% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001518-QINU`"' (1) · Improved with food'"`UNIQ--ref-00000052-QINU`"' (1) · Inhaled lung deposition with minimal systemic absorption (the basis of the favorable safety profile vs systemic antimuscarinics)'"`UNIQ--ref-00000F7C-QINU`"' (1) · Limited but adequate; take with food (1) · Negligible (not absorbed)'"`UNIQ--ref-00000058-QINU`"' (1) · Not characterized; oral dosing once daily (1) · Oral bioavailability of psilocin from administered psilocybin approximately 50% (1) · Oral bioavailability suitable for daily dosing (1) · Oxycodone 60-87%; aspirin 50-75%'"`UNIQ--ref-000014FB-QINU`"' (1) · Topical: minimal systemic absorption (oral systemic 5-FU not used due to poor and variable absorption)'"`UNIQ--ref-000011BF-QINU`"' (1) · Topical: minimal systemic absorption with normal skin; oral: variable, induced metabolism with repeated dosing'"`UNIQ--ref-00000BA4-QINU`"' (1) · Tramadol ~75% (oral); acetaminophen 85-98%'"`UNIQ--ref-00001531-QINU`"' (1) · ~10% inhaled reaches systemic circulation; ~50% PO'"`UNIQ--ref-0000009A-QINU`"' (1) · ~100% (oral, but oral use is limited to continuation from parenteral)'"`UNIQ--ref-00000021-QINU`"' (1) · ~100% (oral; near-complete absorption)'"`UNIQ--ref-00000018-QINU`"' (1) · ~25% (oral, with extensive first-pass)'"`UNIQ--ref-00000023-QINU`"' (1) · ~40-60% (oral, with significant first-pass)'"`UNIQ--ref-00000027-QINU`"' (1) · ~50-60% (oral; food enhances) (1) · ~60-87% oxycodone (high and predictable, less CYP-genotype-dependent than codeine or hydrocodone); 85-98% acetaminophen'"`UNIQ--ref-000014E3-QINU`"' (1) · ~72% (with food); much lower fasting (~36%) (1) · ~75% (1) · ~80% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) · ~80% (oral; reduced by significant first-pass)'"`UNIQ--ref-00000EFA-QINU`"' (1) · ~80-100% (oral)'"`UNIQ--ref-00000027-QINU`"' (1) · ~80-95% (oral; more reliable than furosemide, comparable to torsemide)'"`UNIQ--ref-00000DE4-QINU`"' (1) · ~85-98% (oral)'"`UNIQ--ref-000006A6-QINU`"' (1) · ~95% (1)